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INTRODUCTION 
Toxic epidermal necrolysis (TEN) is a rare, but 
very severe cutaneous disorder characterized by 
necrosis of keratinocytes leading to a loosening of 
the epidermis’**. As a consequence, life- 
threatening dehydration and severe infections 
may occur. TEN can occur as a result of an 
adverse reaction to drugs (i.e. Lye11 syndrome) or 
may be the result of staphylococcal toxins (i.e. 
staphylococcal scalded skin syndrome, SSSS)‘. 
We report a case of TEN following treatment 
with a new antiepileptic drug (AED). 
Lamotrigine (3,5-diamino-6-(2,3-dichlorophen- 
yl)-1,2,4-triazine) has recently been developed for 
oral treatment of epilepsy. Clinical trials have 
shown that lamotrigine is efficacious in controll- 
ing epilepsp. Contraindications to treatment 
are scarce, but include allergy. Reported side- 
effects include: maculopapular rash, angioedema 
and Stevens-Johnson’s syndrome. Minor side- 
effects include diplopia, headache, dizziness, 
ataxia, GI-disturbances and restlessness, but may 
at least in part be attributed to increased 
side-effects of concommitant AEDs’. 
sponse to flickerstimulation and not characteristic 
for juvenile myoclonic epilepsy. She had pre- 
viously been treated with valproic acid, phenytoin 
and vigabatrin. Then she was witout antiepileptic 
medication for two months. Carbamazepine 
medication was started at 100 mg BID wih the 
intention to increase after two weeks, but as the 
patient had no reduction in seizures and as 
lamotrigine was a new possibility, carbamazepine 
was withdrawn and the patient was initated on 
lamotrigine 50mg/day. The dose was increased 
by 50 mg every four days. After 12 days she was 
on lamotrigine monotherapy 100 mg BID and was 
seizure-free. Seventeen days later (i.e. 29 days 
after initiation of lamotrigine monotherapy), the 
patient developed cutaneous symptoms and the 
medication was immediately changed to .pheno- 
barbital 150 mg/day. Later medication was 
changed to a combination of phenobarbital 
150 mg/day and clobazame 25 mg/day with ac- 
ceptable effect on her seizures, but with sedative 
side-effects. 
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Clinical neurology 
The patient was female and aged 24. She suffered 
from myoclonic seizures without loss of concious- 
ness since the age of 21 years. The EEG was 
slightly abnormal without photosensitive re- 
The patient presented no history of skin diseases 
and there were no skin diseases in the family. 
After 30 days on lamotrigine, she developed a 
macular rash on the trunk and extremities and she 
was initially examined at the emergency room 
before referral to the department of dermatology. 
Cutaneous symptoms hereafter rapidly pro- 
gressed to confluence and she had involvement of 
conjunctivae (developing into symblepharon). 
She had lesions of the oral mucosa and had 
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haematuria. On her back and arms the skin was 
greyish with blisters and the epidermis loosened 
over large areas. 
On admission, the patient was treated with 
systemic prednisone (initially intraveneously at a 
dose corresponding to SO mg/day), high potency 
topical steroids, penicillin prophylactically and 
was given intraveneous fluids according to labo- 
ratory tests. Progression of epidermal loss was 
arrested and gradually epidermal regrowth was 
initiated and the skin healed leaving hyperpig- 
mentation of the previously denuded areas. 
Histopathology 
On light microscopy (Fig. I). slides showed 
necrosis of epidermal keratinocytes. no epidermal 
infiltrate and a scarce perivascular dermal 
infiltrate. 
DISCUSSION 
TEN may be the result of an adverse reaction of a 
number of different drugs, sulphonamides being 
the most frequent. Treatment with AEDs has 
previously been shown to be a relatively frequent 
cause of TEN”, but this report seems to be the 
first to show TEN following treatment with 
lamotrigine. 
Ideosyncratic skin rashes are relatively com- 
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mon during lamotrigine treatment. In the first 
controlled studies. rashes occurred in 10 vs. 5% 
on placebo’. In a review of 2380 patients 
participating in clinical studies”‘. 28 patients 
developed rashes characterized as severe and 
leading to withdrawal from the studies. Of these. 
three cases required hospitalization, one with 
rash and systemic manifestations and two with 
symptoms described as Stevens-Johnson’s syn- 
drome. The remaining 25 patients were treated as 
out-patients. One of them had a Stevens- 
Johnson-like syndrome and another had eryth- 
ema multiforme, six were treated with systemic 
steroids while the remaining 17 patients were 
described as having severe maculopapular rashes. 
In a more recent review of 3015 lamotrigine 
treated patients’, serious rashes resulting in 
hospitalization occurred in eight patients. The 
rate of severe rashes thus seems to be about 1% 
and of Stevens-Johnson’s syndrome about 0.1%. 
Our case seems to be the only case developing 
into TEN. The overall incidence of rashes leading 
to discontinuation is 2-3%, which is similar to the 
discontinuation rate with respect to car- 
bamazepine treatment. It seems to be higher 
when the starting dose is high or if lamotrigne is 
given together with valproic acid’.“. However, 
the rate of discontinuation is lower with a lower 
starting dose or when lamotrigine is given 
together with enzyme-inducing AEDs such as 
carbamazepine or phenytoin’.“. The present 
serious case with rash evolving to TEN occurred 
Fig. 1: Photomicrograph of the histology obtained from the skin biopsy specimen showing necrosis of epidermal keratinocytes, 
no epidermal infiltrate and a scarce perivascular dermal infiltrate. (Haematoxylin-eosin stain; magnification x320). Courtesy: 
Dr. H. Sagaard. 
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in a patient not on valproic acid treatment, but in 
whom the dose escalation was very rapid. 3. 
According to a recent report it is suggested that 
bullous cutaneous drug reactions (i.e. bullous 
erythema multiforme, Stevens-Johnson’s syn- 
drome and TEN) are classified according to the 
percentage of body surface involved13. Recent 
studies have been focusing on defects in antigen 
presentation in the skinI and it has been 
suggested that there might exist a genetic 
predisposition to TEN as assessed in vitro15. 
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Diagnosis and treatment of TEN is very 
important because of the high mortality rate”. 
Deaths are mainly caused by hypovolemia and 
sepsis. Treatment with systemic steroids is a 
controversial issue. It is believed that the 
extension of necrolysis can be stopped by 
steroids. On the contrary, it is believed that 
steroids may lead to increased susceptibility to 
infections and impaired wound healing16. In the 
present case high doses of steroids were used, 
because the bullous affection was treated at an 
early stage. 
As TEN is a lifethreatening condition, atten- 
tion should be brought to cutaneous adverse drug 
reaction, not only to AEDs but to all drugs with 
the potential to elicit skin reactions. Regarding 
lamotrigine the newly recommended slow dose 
escalation’ must be taken very seriously to 
minimize such adverse cutaneous drug reactions. 
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